Tower Research Capital LLC TRC raised its holdings in West Pharmaceutical Services Inc. (NYSE:WST) by 453.0% in the 3rd quarter, Holdings Channel reports. The fund owned 6,105 shares of the medical instruments supplier’s stock after acquiring an additional 5,001 shares during the period. Tower Research Capital LLC TRC’s holdings in West Pharmaceutical Services were worth $754,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of WST. Meeder Asset Management Inc. acquired a new position in West Pharmaceutical Services in the 3rd quarter valued at $101,000. Integrated Investment Consultants LLC acquired a new position in West Pharmaceutical Services in the 2nd quarter valued at $155,000. Pendal Group Ltd acquired a new position in West Pharmaceutical Services in the 3rd quarter valued at $181,000. First Allied Advisory Services Inc. acquired a new position in West Pharmaceutical Services in the 2nd quarter valued at $200,000. Finally, Alps Advisors Inc. acquired a new position in West Pharmaceutical Services in the 2nd quarter valued at $206,000. Institutional investors own 92.50% of the company’s stock.
Several brokerages have weighed in on WST. Zacks Investment Research downgraded West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Friday, August 10th. ValuEngine upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Wednesday, October 17th.
WST stock opened at $109.25 on Thursday. The firm has a market cap of $8.09 billion, a PE ratio of 39.30, a PEG ratio of 4.09 and a beta of 1.19. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.94 and a quick ratio of 2.23. West Pharmaceutical Services Inc. has a 52 week low of $82.74 and a 52 week high of $125.09.
West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, October 25th. The medical instruments supplier reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.70 by $0.06. The business had revenue of $431.70 million during the quarter, compared to the consensus estimate of $427.55 million. West Pharmaceutical Services had a return on equity of 15.78% and a net margin of 9.06%. On average, analysts forecast that West Pharmaceutical Services Inc. will post 2.83 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Tower Research Capital LLC TRC Has $754,000 Holdings in West Pharmaceutical Services Inc. (WST)” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/12/06/tower-research-capital-llc-trc-has-754000-holdings-in-west-pharmaceutical-services-inc-wst.html.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Featured Article: How does the Federal Reserve determine interest rates?
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.